Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure

PACE - Pacing and Clinical Electrophysiology

Volumn 26, Issue 5, 2003, Pages 1254-1261

  Aronson, Doron ^a   Mittleman, Murray A ^b   Burger, Andrew J ^b,c  

^a RAMBAM MEDICAL CENTER   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Heart failure; Potassium channels; Sulfonylurea compounds; Ventricular arrhythmias

Indexed keywords

ANTIDIABETIC AGENT; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; STATISTICAL ANALYSIS;

AGED; ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; CHI-SQUARE DISTRIBUTION; DIABETES COMPLICATIONS; DIABETES MELLITUS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; GLIPIZIDE; GLYBURIDE; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POTASSIUM CHANNELS; REGRESSION ANALYSIS; SULFONYLUREA COMPOUNDS; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION;

EID: 0038742932     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.2003.t01-1-00177.x     Document Type: Article

References (43)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
2. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. (comments) Science 1995; 268:423-426.
3. Cook DL, Hales CN. Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature 1984; 311:271-273.
4. Noma A, ATP-regulated K+ channels in cardiac muscle. Nature 1983; 305:147-148.
5. Brady PA, Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998; 31:950-956.
6. Wilde AA, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: Implications for arrhythmogenesis. Cardiovasc Res 1994; 28:16-24.
7. Ferrero JM Jr, Saiz J, Ferrero JM, et al. Simulation of action potentials from metabolically impaired cardiac myocytes. Role of ATP-sensitive K+ current. Circ Res 1996; 79:208-221.
8. Kantor PF, Coetzee WA, Carmeliet EE, et al. Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea. Circ Res 1990; 66:478-485.
9. Cacciapuoti F, Spiezia R, Bianchi U, et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991; 67:843-847.
10. Fosset M, De Weille JR, Green RD, et al. Antidiabetic sulfonylureas control action potential properties in heart cells via high affinity receptors that are linked to ATP-dependent K+ channels. J Biol Chem 1988; 263:7933-7936.
11. Nakaya H, Takeda Y, Tohse N, et al. Effects of ATP-sensitive K+ channel blockers on the action potential shortening in hypoxic and ischaemic myocardium. Br J Pharmacol 1991; 103:1019-1026.
12. Lomuscio A, Vergani D, Marano L, et al. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. Coron Artery Dis 1994; 5:767-771.
13. Schotborgh CE, Wilde AA. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc Res 1997; 34:73-80.
14. Billman GE, Avendano CE, Halliwill JR, et al. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 1993; 21:197-204.
15. Tosaki A, Hellegouarch A. Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion- induced injury. Heart function studies in nonfibrillating isolated hearts. J Am Coll Cardiol 1994; 23:487-496.
16. Sami M, Kraemer H, Harrison DC, et al. A new method for evaluating antiarrhythmic drug efficacy. Circulation 1980; 62:1172-1179.
17. Babenko AP, Aguilar-Bryan L, Bryan J. A view of sur/KIR6.X, KATP channels. Annu Rev Physiol 1998; 60:667-687.
18. Gribble FM, Tucker SJ, Seino S, et al. Tissue specificity of sulfonylureas: Studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes 1998; 47:1412-1418.
19. Ammala C, Moorhouse A, Gribble F, et al. Promiscuous coupling between the sulphonylurea receptor and inwardly rectifying potassium channels. Nature 1996; 379:545-548.
20. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19:789-830.
21. Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. (comments) Circulation 1996; 94:2297-2301.
22. Cleveland JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. (comments) Circulation 1997; 96:29-32.
23. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33:119-124.
24. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subiects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21:220-229.
25. Davis TM, Parsons RW, Broadhurst RJ, et al. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998; 21:637-640.
26. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69:1049-1169.
27. Harris A, Bisteni A, Russel R, et al. Excitatory factors in ventricular tachycardia resulting from myocardial ischemia: Potassium, a major excitant. Science 1954; 119:200-208.
28. Billman GE. Role of ATP sensitive potassium channel in extracellular potassium accumulation and cardiac arrhythmias during myocardial ischaemia. Cardiovasc Res 1994; 28:762-769.
29. Englert HC, Gerlach U, Goegelein H, et al. Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethyl-benzenesulfonylthioureas. J Med Chem 2001; 44:1085-1098.
30. Gogelein H, Hartung J, Englert HC. Molecular basis, pharmacology and physiological role of cardiac K(ATP) channels. Cell Physiol Biochem 1999; 9:227-241.
31. Baukrowitz T, Tucker SJ, Schulte U, et al. Inward rectification in KATP channels: A pH switch in the pore. EMBO J 1999; 18:847-853.
32. Keung EC, Li Q. Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 1991; 88:1772-1777.
33. Unverferth DV, Magorien RD, Lewis RP, et al. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983; 105:176-179.
34. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000; 35:19-28.
35. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96:2190-2196.
36. Liao R, Nascimben L, Friedrich J, et al. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 1996; 78:893-902.
37. Bashore TM, Magorien DJ, Letterio J, et al. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 1987; 9:734-742.
38. Shen W, Asai K, Uechi M, et al. Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: A compensatory role for the parallel loss of creatine. Circulation 1999; 100:2113-2118.
39. Kubo M, Nakaya Y, Matsuoka S, et al. Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ Res 1994; 74:471-476.
40. Funaya H, Kitakaze M, Node K, et al. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997; 95:1363-1365.
41. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410-1420.
42. Findlay I. Interactive regulation of the ATP-sensitive potassium channel of cardiac muscle. J Cardiovasc Pharmacol 1994; 24(Suppl. 4):S6-11.
43. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93:1043-1065.